Comparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients
|
|
- Lionel Harmon
- 6 years ago
- Views:
Transcription
1 Comparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients R Kuefer 1, BG Volkmer 1, M Loeffler 1, RL Shen 2, L Kempf 3, AS Merseburger 4, JE Gschwend 1, RE Hautmann 1, HM Sandler 3,6 & MA Rubin 5,6 * 1 Department of Urology, University of Ulm, Ulm, Germany; 2 Department of Pathology, University of Michigan, School of Medicine, Ann Arbor, Michigan, USA; 3 Department of Radio-Oncology, University of Michigan, School of Medicine, Ann Arbor, Michigan, USA; 4 Department of Urology, University of Tuebingen, Tuebingen, Germany; and 5 Department of Pathology, Brigham & Women s Hospital, Boston, Massachusetts, USA (2004) 7, & 2004 Nature Publishing Group All rights reserved /04 $ Introduction: Treatment options for lymph node positive prostate cancer are limited. We retrospectively compared patients who underwent external radiotherapy (ERT) to patients treated by radical prostatectomy (RPX). Materials and Methods: A total of 102 lymph node positive patients from the RPX series at Ulm University were evaluated. In all, 76 patients received adjuvant androgen withdrawal as part of their primary treatment. In the ERT group, 44 patients were treated at the University of Michigan using a fractionated regimen. Of these, 21 patients received early adjuvant hormonal therapy. Patients with neoadjuvant therapy before RPX or ERT were excluded. Results: In the RPX group, PSA nadir (nadirp0.2 vs 40.2 ng/ml) showed a strong association with outcome. In the ERT group, pretreatment PSA was an independent predictor of outcome (P ¼ 0.04) and patients with adjuvant hormonal therapy had a significant longer recurrence-free interval compared to patients without adjuvant therapy (P ¼ 0.004). Comparing only patients with adjuvant hormonal treatment after cancer-specific therapy, the ERT-treated patients had a borderline longer PSA recurrence-free survival time compared to the RPX-treated patients (P ¼ 0.05). Conclusions: In case of positive lymph nodes, RPX and ERT might be considered and need to be explained to the patient. For future treatment decisions, the presented findings and a potential survival benefit need to be evaluated in a larger prospective setting. (2004) 7, doi: /sj.pcan Published online 7 September 2004 Keywords: external beam radiation therapy; radical prostatectomy; lymph node positive; outcome Introduction Prostate cancer is a leading cause of male cancer-related deaths in the United States. 1 Currently, there is no *Correspondence: MA Rubin, Pathology, Brigham & Women s Hospital, 75 Francis Street, Boston, MA 02115, USA. marubin@partners.org 6 These authors contributed equally to this work. Received 7 April 2004; revised 26 May 2004; accepted 21 June 2004; published online 7 September 2004 standard approach for treating clinically confined and locally advanced prostate cancer. Patients and clinicians deliberate between radical prostatectomy, radiation therapy, and watchful waiting. One recent study provides evidence that men with clinically localized prostate cancer may benefit from radical prostatectomy when compared to watchful waiting due to reduced cancerspecific death and development of metastatic disease in the surgical cohort. 2 For men with locally advanced prostate cancer disease (ie, localized prostate cancer with
2 344 spread to pelvic or regional lymph nodes but no evidence of distant metastatic disease), one may anticipate that treatment decision is easier as it is documented that patients receiving no therapy at all will have a very poor prognosis. 3 5 Yet, only limited comparative data are available concerning different therapeutic options. 6 The goal of the current study was to compare external radiation therapy (ERT) and radical prostatectomy (RPX) in the setting of locally advanced prostate cancer using biochemical failure as the endpoint. Material and methods Patient population At the University of Ulm, Germany, more than 1400 patients underwent RPX since A total of 177 patients had RPX despite the identification of metastatic disease to pelvic lymph nodes during the course of surgery or metastatic spread was identified on the final review of pathology following surgery. Extended lymphadenectomy was carried out and all cases were staged using the TNM classification. 7 Histopathology was re-evaluated by the study pathologist (MAR), who assigned a Gleason score. 8 Patients were grouped according to PSA nadir with a cutoff at 0.2 ng/ ml, those with a PSA o0.2 ng/ml were considered as cases with best local control of tumor. Progression was defined as either an elevation of the PSA level (increase of 40.2 ng/ml compared to PSA nadir) or clinical detectable progress. Follow-up was carried out according to a standardized protocol (physical examination and PSA every 3 months for 2 y after RPX, then twice a year; chest X-ray and bone scan once a year or if suspected). Patients who had received neoadjuvant treatment were excluded. There were 102 men treated by RPX, who fell in this group. At the University of Michigan, USA, 62 patients received ERT for lymph node positive prostate cancer between 1986 and For analysis, the following clinical parameters were required: clinical TNM classification, biopsy Gleason score, pretreatment PSA levels, type of adjuvant therapy, treatment duration and total dose of radiation, and standardized follow-up including evaluation of post-treatment PSA levels. In 45 patients (72.6%), attempted radical prostatectomy was abrogated due to histologically confirmed lymph node metastases. The other 27.4% were diagnosed by enlarged lymph nodes without resection, potentially resulting in a higher tumor burden at time of referral to treatment. ERT was carried out using a fractionated, 3D conformal regimen with an average total dose of 69 Gy (range Gy) applied onto the prostate within 54 days (range days). Failure was defined according to the ASTRO criteria as three consecutive PSA rises compared to nadir. 9 The study population of the ERT group consisted of 44 cases. Detailed demographics are given in Table 1. Table 1 Demographics of the two treatment modalities: radical prostatectomy (RPE) and external radiation therapy (EBRT) Radical prostatectomy Radiation therapy Patient cohort 102 (100%) 44 (100%) Radiation dose (Gy) Mean 69 (45 77 range) Radiation duration (days) Mean 54 (32 76 range) Clinical T1 2 (2%) 2 (5%) Clinical T2 47 (46%) 18 (41%) Clinical T3 51 (50%) 17 (39%) Clinical T4 T stage not assigned 2 (2%) 4 (9%) 3 (6.8) Pathological T1 0 (0%) Pathological T2 5 (5%) Pathological T3 90 (88%) Pathological T4 7 (7%) N1 65 (64%) 23 (52%) N2 37 (36%) 21 (48%) PSA median (ng/ml) 26.1 ( range) 19.9 ( range) Gleason sum RPE specimen Biopsy 6 4 (4%) 5 (11%) 7 24 (24%) 19 (43%) 8 54 (53%) 9 (21%) 9 18 (18%) 2 (5%) 10 2 (2%) 0 (0%) Gleason score not assigned 9 (21%) PSA nadir median (ng/ml) 0.0 ( range) 0.1 ( range) PSA nadir o (62.7%) PSA nadir X (37.3%) Adjuvant treatment 76 (75%) 21 (48%) Hormonal monotherapy 54 (53%) 9 (21%) Complete suppression 22 (22%) 12 (27%) Follow-up median (y) 1.9 ( range) 2.1 ( range) Biochemical failure 60 (59%) 27 (61%) Time till failure median (y) 0.6 ( range) 1.5 ( range) N1 ¼ one affected lymph node; N2 ¼ two or more positive lymph nodes.
3 Data analysis Statistical analysis was performed by a bio-statistician (RLS) applying standard approaches such as the T-test to test for significant difference between the study populations and the Kaplan Meier analysis to estimate survival. Univariate, unmatched comparisons of survival were performed using the log rank test. The Wald test was used for Cox hazards regression analysis in a multivariate model. Results Analysis of the RPX study population All 102 patients of the RPX group underwent surgery with the intention of a surgical cure. The majority of cases had microscopic proven metastases identified in the review of the permanent pathology sections after surgery. Average age at surgery was 64.7 y (range y). The median PSA level before surgery was 26.1 ng/ml (range ng/ml). Two (2%) cases were classified as clinical T1 tumors, 47 (46%) cases as T2, 51 (50%) as T3 and two (2%) cases as clinical T4 tumors. Pathologic evaluation demonstrated that tumor classification was underestimated by the clinical T stage as most of the cases proved to be in the pathology report pt3 (90 patients; 88%). Only five (5%) patients were pt2 and seven (7%) cases T4. In all, 64% of the patients had one positive lymph node after final review of the pathology. All tumors were Gleason score X6. In 64 (62.7%) patients, PSA after surgery dropped o0.2ng/ml, in 38 (37.3%) patients nadir was X0.2 ng/ml. A total of 76 (74.5%) patients received early adjuvant hormonal treatment, 54 patients as monotherapy and 22 patients complete androgen withdrawal. Mean time of follow-up was 2.9 y (range y; 40 (39%) follow-up 43 y). Of the 102 patients, 60 experienced biochemical failure. Median time till failure was 0.6 y (mean 1.5 y; range y). All patients experiencing local or distant recurrence had prior biochemical relapse. Detailed clinical data are given in Table 1 and a graphical presentation of the PSA recurrence-free survival of the 102 RPX cases is given in Figure 1a. To test for associations between clinical parameters and outcome in the RPX group, univariate Cox regression analyses were performed. None of the clinical parameters including age at diagnosis, clinical or pathological tumor stage, lymph node burden, Gleason sum, WHO tumor grade of the prostatectomy specimen, preoperative PSA (numeric value, categorized or logarithmic value) or type of adjuvant hormone treatment demonstrated a statistically significant association with outcome defined as biochemical failure. The only parameter with significant association with outcome was PSA nadir following surgery (Po0.0001, 95% confidence interval (CI) ) (Figure 1b). The best multivariate model for the RPX group eliminated in a stepwise backward procedure all of the clinical parameters mentioned above, calculating a P-value of o for PSA nadir (CI ; hazard risk 2.9). There was no statistically significant difference in recurrence-free survival time based on type of adjuvant treatment (log rank P ¼ 0.46). Only if stratified for PSA nadir, those patients reaching a nadir of PSAo0.2 ng/ml and receiving complete hormonal withdrawal had a longer time of recurrence-free survival compared to those patients receiving mono-therapy (log rank P ¼ 0.03). In the group of patients with a nadir PSAX0.2 ng/ml, there was no association between type of treatment and recurrence-free survival (log rank P ¼ 0.3). Analysis of the ERT study population Since 1986, 44 patients were treated by ERT for lymph node positive prostate cancer at the University of Michigan. Median PSA level before radiotherapy was 19.9 ng/ml (range ng/ml). Two (4.5%) patients had clinical stage T1, 18 (40.9%) patients T2, 17 (38.6%) T3 and four (9.1%) patients T4. Three (6.8%) patients were not assigned a clinical T stage. In all, 52.3% of the patients had one positive lymph node. Five (11.4%) cases had a Gleason sum of 6. A total of 30 (68.2%) patients had a Gleason score of X7 (Gleason ¼ 7, 43.2%; Gleason ¼ 8, 345 Figure 1 (a) Kaplan Meier analysis showing the recurrence-free survival for the group of patients with lymph node positive disease treated by radical prostatectomy. (b) Patients treated by prostatectomy stratified for postoperative prostate-specific antigen nadir o0.2 ng/ml vs X0.2 ng/ml (log rank Po0.0001).
4 %; Gleason ¼ 9, 4.5%). For nine biopsies, a Gleason score was not available for analysis. Median nadir was a PSA of 0.1 ng/ml ( ng/ml). In all, 21 (47.8%) patients received adjuvant treatment, nine (20.5%) patients monotherapy and 12 (27.3%) patients complete androgen deprivation. Median follow-up time was 2.1 y (range y; mean 3.2 y; 15 (34%) follow-up 43 y). Of the 44 patients, 27 (61.4%) had biochemical failure. Median time to failure was 1.5 y (range y). A graphical presentation of the recurrence-free survival data of the 44 ERT treated cases is given in Figure 2a. Of all clinical parameters, tumor stage (Cox regression P ¼ 0.005, CI ) and pretreatment PSA (P ¼ 0.007, CI 95% ) had a strong association with outcome on the univariate level. In the ERT group, there is a significant higher percentage of patients with freedom from recurrence if adjuvantly treated by any type of early hormonal withdrawal (P ¼ 0.004) (Figure 2b). There was statistically no difference if treated with monotherapy or complete hormonal withdrawal (log rank P ¼ 0.38). The multivariate model calculated a P-value of for pretreatment PSA if categorized into three groups PSAo10 ng/ml, PSA410 and o20 ng/ml and PSA420 ng/ml (CI ). In this setting, adjuvant hormonal therapy had the strongest association with PSA recurrence-free survival in patients treated with ERT (Po0.001; CI ). Comparison of the two treatment modalities: RPX and ERT For comparison of the two treatment options, we first looked at patients who had received some kind of adjuvant hormonal therapy. With this approach, it is taken into consideration that adjuvant treatment had a significant influence on outcome in the ERT group. In the RPX group, independent of nadir, there was no strong association between type of adjuvant hormone therapy and outcome as described above. The RPX group consisted of 76 patients. In all, 45 patients experienced biochemical failure during follow-up; median follow-up was 1.6 y (mean 3.1 y; range y). The ERT group consisted of 21 cases of which seven had PSA relapse during follow-up; median follow-up was 2.3 y (mean 3.3 y; range y). There was no significant difference in the pretreatment clinical parameters between these two groups including tumor stage (T-test P ¼ 0.6), lymph node burden (P ¼ 0.7) and PSA (P ¼ 0.06). As demonstrated in Figure 3a, the Kaplan Meier survival curve revealed a borderline significant difference in PSA recurrence-free survival rate between these two groups (log rank P ¼ 0.053). Interestingly, the ERT group reached a plateau at about 50% PSA recurrencefree survival, starting at a follow-up time of 4 y. In contrast to that, in the RPX group, the survival curve of the patients receiving some sort of adjuvant hormonal therapy, does not reach a plateau up to 12 y after RPX. Complete hormonal withdrawal has, in both treatment groups, some, but not a statistically significant, benefit compared to monotherapy (RPX log rank P ¼ 0.36; ERT log rank P ¼ 0.38). As demonstrated in Figure 3b, when comparing only patients with complete hormonal withdrawal after cancer-specific therapy, there is no difference in PSA recurrence-free survival between the RPX and the ERT group (log rank P ¼ 0.37). In this comparison, all patients independent of nadir were included in the RPX group, as postsurgical nadir cannot be used as a parameter to preselect patients for RPX. Discussion Currently for men diagnosed with clinically localized and locally advanced prostate cancer, there is no definitive single best treatment option. Some guidelines have been developed to evaluate men on watchful waiting protocols. 10 A recent study provides evidence that in clinically localized prostate cancer, radical prostatectomy may reduce the cancer-specific but not the overall mortality compared to watchful waiting. 2 At first glance, the debate regarding treatment seems easier in locally advanced disease, as it is known that patients with node positive disease, receiving no therapy will die due to prostate cancer within a short period of time. 11 But in these cases, the question is what type of therapy is of most long-term benefit to the majority of patients? Figure 2 (a) Kaplan Meier analysis showing the recurrence-free survival for the group of patients with lymph node positive disease treated by ERT. (b) Freedom from recurrence of patients after radiation stratified for type of adjuvant hormonal treatment. Patients receiving no adjuvant hormonal therapy vs patients with adjuvant androgen withdrawal (log rank P ¼ 0.014).
5 347 Figure 3 (a) Kaplan Meier analysis comparing the recurrence-free survival of patients treated by radical prostatectomy vs patients who underwent external radiation therapy. Both groups received adjuvant hormonal treatment either by monotherapy or complete hormonal withdrawal (log rank P ¼ 0.05). (b) Comparison of the recurrence-free survival of patients who received complete hormonal withdrawal after radical prostatectomy or ERT. Radiation therapy as an option in the treatment for prostate cancer goes back to the 1960 s. Technical advances and application of field techniques have helped reduce complications and only in the minority of cases do patients report moderate urinary and bowel symptoms. 12,13 In prostate cancer, the gross disease requires radiation doses of at least 70 Gy applied in a fractionated regimen. The median dose in this study was 69 Gy and thus is quite low. Such low doses are likely suboptimal for treatment. In fact, there is evidence that increased doses are associated with reduced risk of biochemical failure, distant metastasis and even overall survival Controversy exists if there is a benefit to irradiation of the pelvic lymph nodes with a total dose of about 45 Gy. A study conducted by the RTOG failed to show a benefit in treating lymph nodes and prostate compared to prostate alone in prostate cancer A2 and B tumors. 17 This observation is supported by another study including lymph node positive prostate cancer patients. 18 No clear benefit is described in the literature from prophylactic pelvic nodal irradiation compared to prostate-only radiation. Yet, according to the RTOG 9413 study, there is a benefit of whole pelvic radiotherapy if combined with neoadjuvant and concurrent hormonal therapy compared to radiotherapy of the prostate-only with any type of hormonal withdrawal. 19 Radical prostatectomy combined with adjuvant hormonal therapy is considered a valuable treatment option in high-risk prostate cancer patients. 20 In the presence of positive lymph nodes, it has been demonstrated that immediate antiandrogen therapy reduces the risk of recurrence and improves survival compared to observation. 21 Surgery often is stopped once positive lymph nodes are discovered during lymphadenectomy. Still some benefit through surgery and adjuvant hormonal treatment in these advanced cases is reported. 5,11,22 In fact, there is evidence that radical prostatectomy with early adjuvant androgen deprivation provides a significant advantage compared to androgen suppression alone as goes for overall and disease-specific survival. 23 Presently, less advanced cases are diagnosed due to increasing awareness of the population and the merit of PSA as a screening tool. On the other hand, a recent series from Europe shows minute lymph node metastases in about 40% of all cases including cases with a low pathological tumor stage. In this study, examination of iliac lymph nodes from the external and internal region was examined. 24 These findings suggest that at least some published outcome results after RPX had a significant number of cases with lymph node positive disease, included as pn0 disease. A critical issue in comparing the results of two treatment modalities in this or any study is the choice of exclusion criteria and the definition of outcome. In this study, all patients with any kind of neoadjuvant treatment have been excluded. For patients treated with RPX, neoadjuvant hormonal therapy is still considered controversial and not generally recommended. 25,26 For patients treated with ERT, neoadjuvant therapy is promising to have an influence even on disease-free and overall survival. 27 Adjuvant treatment has been grouped the RPX and the ERT patients into three categories, no adjuvant treatment, monotherapy and complete androgen deprivation. Although it has been suggested in previous studies that early adjuvant androgen deprivation is beneficial for patients with node positive disease treated by RPX, 21,28,29 surprisingly a considerable number of patients did not receive adjuvant hormonal therapy. The same is true for the ERT group. In accordance with the findings in this study and supported by in vitro and in vivo experiments, 30 early adjuvant hormonal treatment has been shown to be beneficial in bulky tumors Crucial for comparison of the results is the choice of endpoint. In the current series, there have not been enough disease-specific deaths, that is, three in the ERT group, for comparative statistical analysis. This points out the importance of even longer follow-up times. The endpoint was defined as biochemical failure measured by PSA. For all interpretations in this setting, it has to be kept in mind that the most common, but still different definitions of failure, have been applied for the two treatment options. It cannot be ruled out that the differences seen might be only related to the calculation of PSA failure or the expected kinetics after specific therapy. For radiation therapy, there is significant controversy about definition of the appropriate nadir. It is known that after radiation therapy, PSA levels decline
6 348 over a period of several years. It is unclear if the time till nadir is associated with risk of biochemical failure but, in one study, it was demonstrated that a nadir of less than 1 ng/ml is an independent predictor of biochemical outcome. 35 In the current study, we applied to the ERT group the ASTRO criteria, 9 although variations in results due to different criteria and potential improvements of the ASTRO criteria have been described. 36,37 For the RPX group, biochemical failure was defined as a PSA increase over 0.2 ng/ml compared to nadir. For comparison with the ERT group, those patients not reaching undetectable PSA levels after RPX were not excluded, although these cases obviously represent unsatisfactory surgical control and might be defined as failures at day zero in other studies. So not surprisingly, there was a strong association between nadir and biochemical failure in the RPX group. This is a post-treatment parameter and thus cannot be taken into consideration for treatment decision. Analysis of the RPX group demonstrated that an optimal surgical result is mandatory for an additional significant positive effect of adjuvant hormonal deprivation. As described in detail above, patients treated by ERT and adjuvant hormonal therapy had statistically a borderline significant better outcome than patients after RPX and adjuvant hormonal therapy. This difference diminishes if best surgical condition was achieved reflected by a PSA nadir of o0.2 ng/ml. In this case, patients treated by RPX and receiving some adjuvant hormonal treatment do as well as patients treated by ERT and adjuvant hormonal treatment (log rank 0.47). Obviously, there is no possibility to predict a PSA nadir of o0.2 ng/ml after RPX. Therefore, we believe that the rationale for the comparison between these two treatment groups of men with locally advanced prostate cancer is appropriate. On the other hand, analysis demonstrated that a patient reaching a PSA nadir of o0.2 ng/ml and receiving complete hormonal withdrawal has almost a 80% chance not to experience biochemical failure within 10 y after surgery (data not shown). Furthermore, one may state that patients treated by RPX and not reaching a PSA nadir of o0.2 ng/ml will need some other sort of adjuvant therapy as hormonal withdrawal does not seem to have a major influence. In this group, ERT might be a very good option of adjuvant treatment after RPX. 38 Our data also suggest that in patients treated with ERT, adjuvant therapy by the means of hormonal withdrawal, is beneficial. The different mechanisms represented by radiotherapy and hormonal deprivation concerning control or killing of malignant cells suggest a rationale for their combined use. In the RPX group, it is demonstrated that long-term success primarily depends on a perfect local control and thus surgical success. In this setting, hormonal therapy shows an additive effect on PSA recurrence-free survival. Conclusions Acknowledging the fact that morbidity and mortality of both treatment options, RPX and ERT, have been significantly decreasing due to technical improvements, both therapy modalities have to be considered and explained to the patient in case of positive lymph nodes. If a PSA nadir of o0.2 ng/ml is not reached after RPX, additional therapy (ie ERT) is indicated as hormonal withdrawal is not sufficient. Acknowledgements This study was supported by the Specialized Program of Research Excellence for Prostate Cancer (S.P.O.R.E.) NCI Grant no. P50CA References 1 Jemal A et al. Cancer statistics, CA Cancer J Clin 2002; 52: Holmberg L et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347: Davidson PJ et al. Progression in untreated carcinoma of the prostate metastatic to regional lymph nodes (stage t0 to 4,N1 to 3.M0,D1). European Organization for Research and Treatment of Cancer Genitourinary Group. JUrol1995; 154: Seay TM, Blute ML, Zincke H. Long-term outcome in patients with ptxn+adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. J Urol 1998; 159: Zwergel U et al. Lymph node positive prostate cancer: long-term survival data after radical prostatectomy. J Urol 2004; 171: Pollack A, Horwitz EM, Movsas B. Treatment of prostate cancer with regional lymph node (N1) metastasis. Semin Radiat Oncol 2003; 13: Fleming ID, Cancer AJCo, (U.S.) NCI. AJCC Cancer Staging Manual, 5th ed., Philadelphia: Lippincott-Raven, Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep 1966; 50: American Society for Therapeutic Radiology aocp. Consensus Statement: Guidlines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997; 37: Choo R et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. JUrol2002; 167: Seay TM, Blute MC, Zincke H. Radical prostatectomy and early adjuvant hormonal therapy for ptxn+ adenocarcinoma of the prostate. Urology 1997; 50: Sandler HM et al. Three dimensional conformal radiotherapy for the treatment of prostate cancer: low risk of chronic rectal morbidity observed in a large series of patients. Int J Radiat Oncol Biol Phys 1995; 33: Fukunaga-Johnson N et al. Results of 3D conformal radiotherapy in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 1997; 38: Michalski JM et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG Int J Radiat Oncol Biol Phys 2000; 46: Ryu JK et al. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 gy). Int J Radiat Oncol Biol Phys 2002; 54: Jacob R et al. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer 2004; 100: Asbell SO et al. Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG Int J Radiat Oncol Biol Phys 1988; 15: Leibel SA et al. The effects of local and regional treatment on the metastatic outcome in prostatic carcinoma with pelvic
7 lymph node involvement. Int J Radiat Oncol Biol Phys 1994; 28: Roach III M et al. Phase III trial comparing whole-pelvic vs prostate-only radiotherapy and neoadjuvant vs adjuvant combined androgen suppression: Radiation Therapy Oncology Group J Clin Oncol 2003; 21: Vaishampayan U, Hussain M. The evolving role of systemic therapy in high risk prostate cancer: strategies for cure in the 21st century. Crit Rev Oncol Hematol 2002; 42: Messing EM et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: Samson D-J et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002; 95: Ghavamian R et al. Radical retropubic prostatectomy plus orchiectomy vs orchiectomy alone for ptxn+prostate cancer: a matched comparison. J Urol 1999; 161: , discussion Heidenreich A, Varga Z, Von-Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. JUrol2002; 167: Wieder JA, Soloway MS. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. JUrol1998; 160: Gleave ME et al. Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up. Urology 2000; 56: Bolla M et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: Zincke H et al. Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumors. Cancer 1992; 70 (1 Suppl): Frohmuller HG et al. Survival and quality of life of patients with stage D1 (T1-3 pn1-2 M0) prostate cancer. Radical prostatectomy plus androgen deprivation vs androgen deprivation alone. Eur Urol 1995; 27: Zietman AL et al. The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: an in vitro and in vivo study. Cancer J Sci Am 1997; 3: Pilepich MV et al. Phase III radiation therapy oncology group (RTOG) trial of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: Whittington R et al. The use of combined radiation therapy and hormonal therapy in the management of lymph nodepositive prostate cancer. Int J Radiat Oncol Biol Phys 1997; 39: Sands ME, Pollack A, Zagars GK. Influence of radiotherapy on node-positive prostate cancer treated with androgen ablation. Int J Radiat Oncol Biol Phys 1995; 31: Zagars GK, Pollack A, von-eschenbach AC. Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. Urology 2001; 58: Zelefsky MJ et al. Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostatic cancer. J Clin Oncol 1995; 13: Cherullo EE et al. Variable definitions influence the reporting of biochemical failure rates. Prostate Cancer and Prostatic Disease 2002; 5: Taylor JM, Griffith KA, Sandler HM. Definitions of biochemical failure in prostate cancer following radiation therapy. Int J Radiat Oncol Biol Phys 2001; 50: Kalapurakal JA et al. Biochemical disease-free survival following adjuvant and salvage irradiation after radical prostatectomy. Int J Radiat Oncol Biol Phys 2002; 54:
Outcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationHIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED PROSTATE CANCER
0022-5347/01/1663-0876/0 THE JOURNAL OF UROLOGY Vol. 166, 876 881, September 2001 Copyright 2001 by AMERICAN UROLOGICAL ASSOCIATION, INC. Printed in U.S.A. HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED
More informationTiming of Androgen Deprivation: The Modern Debate Must be conducted in the following Contexts: 1. Clinical States Model
Timing and Type of Androgen Deprivation Charles J. Ryan MD Associate Professor of Clinical Medicine UCSF Comprehensive Cancer Center Timing of Androgen Deprivation: The Modern Debate Must be conducted
More informationClinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center
Advances in Urology Volume 22, Article ID 64263, 8 pages doi:.55/22/64263 Clinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center D. Milonas, G. Smailyte,
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationProstate Cancer in comparison to Radiotherapy alone:
Prostate Cancer in comparison to Radiotherapy alone: 1 RTOG 86-10 (2001) 456 patients with > a-goserelin 2 month before RTand during RT + Cyproterone acetate (1 month) vs b-pelvic irradiation (50 gy) +
More informationVol. 36, pp , 2008 T1-3N0M0 : T1-3. prostate-specific antigen PSA. 68 Gy National Institutes of Health 10
25 Vol. 36, pp. 25 32, 2008 T1-3N0M0 : 20 2 18 T1-3 N0M0 1990 2006 16 113 59.4-70 Gy 68 Gy 24 prostate-specific antigen PSA 1.2 17.2 6.5 5 91 95 5 100 93 p 0.04 T3 PSA60 ng ml 68 Gy p 0.0008 0.03 0.04
More informationPSA is rising: What to do? After curative intended radiotherapy: More local options?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung
More informationBone Metastases in Muscle-Invasive Bladder Cancer
Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No. 3, September: 03-08, 006 AZZA N. TAHER, M.D.* and MAGDY H. KOTB, M.D.** The Departments of Radiation Oncology* and Nuclear Medicine**, National Cancer
More informationImpact of Adjuvant Androgen-Deprivation Therapy on Disease Progression in Patients with Node-Positive Prostate Cancer
www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.11.741 Urological Oncology Impact of Adjuvant Androgen-Deprivation Therapy on Disease Progression in Patients with Node-Positive Prostate Cancer
More informationProject approved by the Fondo de investigaciones Socio Sanitarias (FISS). Resolution dated June 8, Official State Gazette: June 17, 2004.
Edition No. 01 Phase III randomized and multicenter trial of adjuvant androgen deprivation combined with high-dose 3-dimensional conformal radiotherapy in intermediate- or high-risk localized prostate
More informationStrategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer
Strategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer Daisaku Hirano, MD Department of Urology Higashi- matsuyama Municipal Hospital, Higashi- matsuyama- city, Saitama- prefecture,
More informationThe Phoenix Definition of Biochemical Failure Predicts for Overall Survival in Patients With Prostate Cancer
55 The Phoenix Definition of Biochemical Failure Predicts for Overall Survival in Patients With Prostate Cancer Matthew C. Abramowitz, MD 1 Tiaynu Li, MA 2 Mark K. Buyyounouski, MD 1 Eric Ross, PhD 2 Robert
More informationWhen radical prostatectomy is not enough: The evolving role of postoperative
When radical prostatectomy is not enough: The evolving role of postoperative radiation therapy Dr Tom Pickles Clinical Associate Professor, UBC. Chair, Provincial Genito-Urinary Tumour Group BC Cancer
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationSalvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes
ORIGINAL RESEARCH Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes Michael J. Metcalfe, MD ; Patricia Troncoso, MD 2 ; Charles C. Guo,
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationEvaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationRadiation Therapy After Radical Prostatectomy
Articles ISSN 1537-744X; DOI 10.1100/tsw.2004.93 Radiation Therapy After Radical Ali M. Ziada, M.D. and E. David Crawford, M.D. Division of Urology, University of Colorado, Denver, Colorado E-mails: aziada@mednet3.camed.eun.eg
More informationSubject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOO Subject Index Androgen antiandrogen therapy, see Hormone ablation therapy, synthesis and metabolism 49 Bacillus Calmette-Guérin adjunct therapy with transurethral resection
More informationCorrespondence should be addressed to Taha Numan Yıkılmaz;
Advances in Medicine Volume 2016, Article ID 8639041, 5 pages http://dx.doi.org/10.1155/2016/8639041 Research Article External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score
More informationRadiation dose has been reported to be an important determinant
538 The Relationship of Increasing Radiotherapy Dose to Reduced Distant Metastases and Mortality in Men with Prostate Cancer Rojymon Jacob, M.D. 1 Alexandra L. Hanlon, Ph.D. 2 Eric M. Horwitz, M.D. 1 Benjamin
More information2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
More informationRadical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience
MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,
More informationjournal of medicine The new england Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy abstract
The new england journal of medicine established in 1812 july 8, 4 vol. 31 no. 2 Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy Anthony V. D Amico, M.D.,
More informationHeterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy
Cagney et al. BMC Urology (2017) 17:60 DOI 10.1186/s12894-017-0250-2 RESEARCH ARTICLE Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationOverview of Radiotherapy for Clinically Localized Prostate Cancer
Session 16A Invited lectures: Prostate - H&N. Overview of Radiotherapy for Clinically Localized Prostate Cancer Mack Roach III, MD Department of Radiation Oncology UCSF Helen Diller Family Comprehensive
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationSupported by M. D. Anderson Cancer Center physician investigator funds. We thank Gerald E. Hanks, MD, for help and guidance with this project.
1496 Biochemical and Clinical Significance of the Posttreatment Prostate-Specific Antigen Bounce for Prostate Cancer Patients Treated With External Beam Radiation Therapy Alone A Multiinstitutional Pooled
More informationHormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice
european urology supplements 5 (2006) 362 368 available at www.sciencedirect.com journal homepage: www.europeanurology.com Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice Antonio
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationProstate Cancer Local or distant recurrence?
Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationGUIDELINES ON PROSTATE CANCER
10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal
More informationCONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM
RAPID COMMUNICATION CME ARTICLE CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM ALAN W. PARTIN, LESLIE A. MANGOLD, DANA M. LAMM, PATRICK C. WALSH, JONATHAN
More informationEORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924
EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924 Title of the Study Medical Condition Androgen deprivation therapy and high dose radiotherapy with or without
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationRadical Prostatectomy versus Intensity Modulated Radiation Therapy in the Management of Localized Prostate Cancer
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 10-19-2009 Radical Prostatectomy versus Intensity Modulated Radiation
More informationRadiotherapy for Localized Hormone-refractory Prostate Cancer in Japan
Radiotherapy for Localized Hormone-refractory Prostate Cancer in Japan KATSUMASA NAKAMURA 1, TERUKI TESHIMA 2, YUTAKA TAKAHASHI 2, ATSUSHI IMAI 3, MASAHIKO KOIZUMI 4, NORIO MITSUHASHI 5, YOSHIYUKI SHIOYAMA
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationBiochemical progression-free survival in localized prostate cancer patients treated with definitive external beam radiotherapy
Electronic Physician (ISSN: 2008-5842) http://www.ephysician.ir October 2015, Volume: 7, Issue: 6, Pages: 1330-1335, DOI: 10.14661/1330 Biochemical progression-free survival in localized prostate cancer
More informationManaging Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps?
Managing Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps? Michael J Zelefsky, M.D. Professor of Radiation Oncology Chief Brachytherapy Service Department of Radiation Oncology
More informationin 32%, T2c in 16% and T3 in 2% of patients.
BJUI Gleason 7 prostate cancer treated with lowdose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure Richard G. Stock, Joshua Berkowitz, Seth R. Blacksburg and Nelson
More informationJure Murgic 1, Matthew H Stenmark 1, Schuyler Halverson 1, Kevin Blas 1, Felix Y Feng 1,2 and Daniel A Hamstra 1,3*
Murgic et al. Radiation Oncology 2012, 7:127 RESEARCH Open Access The role of the maximum involvement of biopsy core in predicting outcome for patients treated with dose-escalated radiation therapy for
More informationNew Technologies for the Radiotherapy of Prostate Cancer
Prostate Cancer Meyer JL (ed): IMRT, IGRT, SBRT Advances in the Treatment Planning and Delivery of Radiotherapy. Front Radiat Ther Oncol. Basel, Karger, 27, vol. 4, pp 315 337 New Technologies for the
More informationSRO Tutorial: Prostate Cancer Clinics
SRO Tutorial: Prostate Cancer Clinics May 7th, 2010 Daniel M. Aebersold Klinik und Poliklinik für Radio-Onkologie Universität Bern, Inselspital Is cure necessary in those in whom it may be possible, and
More informationGUIDELINEs ON PROSTATE CANCER
GUIDELINEs ON PROSTATE CANCER (Text update March 2005: an update is foreseen for publication in 2010. Readers are kindly advised to consult the 2009 full text print of the PCa guidelines for the most recent
More informationJ Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION
VOLUME 26 NUMBER 4 FEBRUARY 1 28 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Short-Term Neoadjuvant Androgen Deprivation Therapy and External-Beam Radiotherapy for Locally Advanced Prostate
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationChanges in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer
Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer S Egawa 1 *, H Okusa 1, K Matsumoto 1, K Suyama 1 & S Baba 1 1 Department
More informationAccuracy of post-radiotherapy biopsy before salvage radical prostatectomy
Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy Joshua J. Meeks, Marc Walker*, Melanie Bernstein, Matthew Kent and James A. Eastham Urology Service, Department of Surgery and
More informationconcordance indices were calculated for the entire model and subsequently for each risk group.
; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationPrognostic value of the Gleason score in prostate cancer
BJU International (22), 89, 538 542 Prognostic value of the Gleason score in prostate cancer L. EGEVAD, T. GRANFORS*, L. KARLBERG*, A. BERGH and P. STATTIN Department of Pathology and Cytology, Karolinska
More informationVALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE. ELENA CASTRO Spanish National Cancer Research Centre
VALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 17-18 October 2017 Prostate Specific Antigen (PSA) has a role in:
More informationResearch Article Long-Term Oncological Outcomes for Young Men Undergoing Radical Prostatectomy for Localized Prostate Cancer
Hindawi BioMed Research International Volume 2017, Article ID 9858923, 6 pages https://doi.org/10.1155/2017/9858923 Research Article Long-Term Oncological Outcomes for Young Men Undergoing Radical Prostatectomy
More informationCLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE II
More informationA comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer
ORIGINAL RESEARCH A comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer Daniel Taussky, MD; 1 Véronique Ouellet, MD; 2 Guila Delouya,
More informationOpen clinical uro-oncology trials in Canada
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD, Mary J. Mackenzie, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES CISPLATIN-BASED
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS
More informationdoi: /s (03) CLINICAL INVESTIGATION
doi:10.1016/s0360-3016(03)01746-2 Int. J. Radiation Oncology Biol. Phys., Vol. 58, No. 4, pp. 1048 1055, 2004 Copyright 2004 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/04/$ see front
More informationHigh Risk Localized Prostate Cancer Treatment Should Start with RT
High Risk Localized Prostate Cancer Treatment Should Start with RT Jason A. Efstathiou, M.D., D.Phil. Assistant Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School 10
More informationRadiation with oral hormonal manipulation for non-metastatic, intermediate or high risk prostate cancer in men 70 and older or with comorbidities
Radiation with oral hormonal manipulation for non-metastatic, intermediate or high risk prostate cancer in men 70 and older or with comorbidities Prostate cancer is predominately a disease of older men,
More informationRadical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease
Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after
More informationImpact of the duration of hormonal therapy following radiotherapy for localized prostate cancer
ONCOLOGY LETTERS 10: 255-259, 2015 Impact of the duration of hormonal therapy following radiotherapy for localized prostate cancer MITSURU OKUBO, HIDETUGU NAKAYAMA, TOMOHIRO ITONAGA, YU TAJIMA, SACHIKA
More informationQ&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1
Collecting Cancer Data: Prostate NAACCR 2010-2011 Webinar Series May 5, 2011 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview NAACCR 2010-2011 Webinar Series 1
More informationRobotic assisted pelvic lymph node dissection for prostate cancer: frequency of nodal metastases and oncological outcomes
UROLCHI World J Urol DOI 10.1007/s00345-015-1515-6 ORIGINAL ARTICLE Robotic assisted pelvic lymph node dissection for prostate cancer: frequency of nodal metastases and oncological outcomes Rodrigo A.
More informationPredictive factors of late biochemical recurrence after radical prostatectomy
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2017, 47(3) 233 238 doi: 10.1093/jjco/hyw181 Advance Access Publication Date: 9 December 2016 Original Article Original
More informationPET imaging of cancer metabolism is commonly performed with F18
PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism
More informationIntensity Modulated Radiotherapy (IMRT) of the Prostate
Medical Policy Manual Medicine, Policy No. 137 Intensity Modulated Radiotherapy (IMRT) of the Prostate Next Review: August 2018 Last Review: November 2017 Effective: December 1, 2017 IMPORTANT REMINDER
More informationOutcome of Surgery for Clinical Unilateral T3a Prostate Cancer: A Single-Institution Experience
european urology 51 (2007) 121 129 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Outcome of Surgery for Clinical Unilateral T3a Prostate Cancer: A Single-Institution
More informationRadiation therapy after radical prostatectomy: A single-centre radiation oncology experience in trends of referral and treatment practices
Original original research Radiation therapy after radical prostatectomy: A single-centre radiation oncology experience in trends of referral and treatment practices Michel Zimmermann, MD; * Daniel Taussky,
More informationRare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital
E-Da Medical Journal 20;():-5 Original Article Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital Wei-Ting Kuo, I-Wei Chang2, Kevin Lu, Hua-Pin Wang, Tsan-Jung u, Victor C.
More informationBJUI. Long-term overall survival and metastasis-free survival for men with prostate-specific antigenrecurrent
21 THE AUTHORS; 21 Urological Oncology DETERMINANTS OF SURVIVAL IN PSA-RECURRENT PROSTATE CANCER AFTER PROSTATECTOMY ANTONARAKIS ET AL. BJUI Long-term overall survival and metastasis-free survival for
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES CISPLATIN-BASED
More informationThe use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective randomised trials
British Journal of Cancer (2004) 90, 950 954 All rights reserved 0007 0920/04 $25.00 www.bjcancer.com Minireview The use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective
More informationAram Kim 4, Myong Kim 1, Se Un Jeong 2, Cheryn Song 1, Yong Mee Cho 2, Jae Yoon Ro 3 and Hanjong Ahn 1*
Kim et al. BMC Urology (2018) 18:7 DOI 10.1186/s12894-018-0321-z RESEARCH ARTICLE Open Access Level of invasion into fibromuscular band is an independent factor for positive surgical margin and biochemical
More informationDefinition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
More informationOutcome of Prostate Cancer Patients with Initial PSA I 20 ng/ml Undergoing Radical Prostatectomy
european urology 52 (2007) 1058 1066 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Outcome of Prostate Cancer Patients with Initial PSA I 20 ng/ml Undergoing
More informationRisk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy
RESEARCH ARTICLE Risk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy Satoru Taguchi, Hiroshi Fukuhara*, Shigenori Kakutani,
More informationincision into an otherwise organ-confined cancer [1,5].
28 The Authors. Journal compilation 28 BJU International Original Article IMPACT ON PROGRESSION OF POSITIVE SURGICAL MARGINS AFTER RP PFITZENMAIER et al. BJUI BJU INTERNATIONAL Positive surgical margins
More informationChapter 6. Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma. Abstract
Chapter 6 Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma Vijaya Raj Bhatt 1, Carl M Post 2, Sumit Dahal 3, Fausto R Loberiza 4 and Jue Wang 4 * 1 Department
More informationHormonal Treatment and other Options in men with locally Advanced Prostate Cancer. Seoul Veterans Hospital Department of Urology Tae Young Jung
Hormonal Treatment and other Options in men with locally Advanced Prostate Cancer Seoul Veterans Hospital Department of Urology Tae Young Jung Introduction Watchful waiting / Androgen deprivation therapy
More informationRADICAL PROSTATECTOMY IS SElected
ORIGINAL CONTRIBUTION Adjuvant for Pathologically Advanced Prostate Cancer A Randomized Clinical Trial Ian M. Thompson, Jr, MD Catherine M. Tangen, DrPH Jorge Paradelo, MD M. Scott Lucia, MD Gary Miller,
More informationLong-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with Radical Prostatectomy
Jpn J Clin Oncol 2012;42(6)541 547 doi:10.1093/jjco/hys043 Advance Access Publication 28 March 2012 Long-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with
More informationExternal Beam Radiation Therapy for Low/Intermediate Risk Prostate Cancer
External Beam Therapy for Low/Intermediate Risk Prostate Cancer Jeff Michalski, M.D. The Carlos A. Perez Distinguished Professor of Department of and Siteman Cancer Center Learning Objectives Understand
More informationdoi: /j.ijrobp CLINICAL INVESTIGATION
CME doi:10.1016/j.ijrobp.2010.07.2004 Int. J. Radiation Oncology Biol. Phys., Vol. 81, No. 5, pp. 1293 1301, 2011 Copyright Ó 2011 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/$ - see
More informationTreatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy
Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo
More information2/14/09. Why Discuss this topic? Managing Local Recurrences after Radiation Failure. PROSTATE CANCER Second Treatment
Why Discuss this topic? Mack Roach III, MD Professor and Chair Radiation Oncology UCSF Managing Local Recurrences after Radiation Failure 1. ~15 to 75% of CaP pts recur after definitive RT. 2. Heterogeneous
More informationDivision of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine, Durham, NC
LHRH AGONISTS: CONTEMPORARY ISSUES The Evolving Definition of Advanced Prostate Cancer Judd W. Moul, MD, FACS Division of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine,
More informationTreatment Failure After Primary and Salvage Therapy for Prostate Cancer
307 Treatment Failure After Primary and Salvage Therapy for Prostate Cancer Likelihood, Patterns of Care, and Outcomes Piyush K. Agarwal, MD 1 Natalia Sadetsky, MD, MPH 2 Badrinath R. Konety, MD, MBA 2
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND
More informationHow Should WeTreat Patients with Locally Advanced Prostate Cancer?
European Urology Supplements European Urology Supplements 2 (2003) 14 22 How Should WeTreat Patients with Locally Advanced Prostate Cancer? Malcolm Mason * Section of Oncology and Palliative Medicine,
More informationPrognostic Value of Surgical Margin Status for Biochemical Recurrence Following Radical Prostatectomy
Original Article Japanese Journal of Clinical Oncology Advance Access published January 17, 2008 Jpn J Clin Oncol doi:10.1093/jjco/hym135 Prognostic Value of Surgical Margin Status for Biochemical Recurrence
More informationClinical and biochemical outcomes of men undergoing radical prostatectomy or radiation therapy for localized prostate cancer
Original Article Radiat Oncol J 205;33():2-28 http://dx.doi.org/0.3857/roj.205.33..2 pissn 2234-900 eissn 2234-356 Clinical and biochemical outcomes of men undergoing radical prostatectomy or radiation
More informationNational Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:
Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A PHASE III STUDY OF IRESSA
More information